CD4 and infection: These results, together with the proof of principle of the potential benefit of using anti-CMV treatments in ANCA-Associated Vasculitis, support the possible application of anti-CMV therapy in any clinical situation where CD4+CD57+ T-cells are implicated, including impaired responses to infection and vaccination.